Methotrexaat Basic Pharma (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a co‑factor needed for DNA, RNA, and protein synthesis. By limiting nucleotide formation, the drug reduces proliferation of rapidly dividing cells such as activated immune cells and malignant lymphoblasts, providing immunosuppressive and antineoplastic effects.

The specific dose of Methotrexaat Basic Pharma is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment goals. Dosing regimens can vary widely between indications, and the prescriber will tailor the schedule to achieve optimal therapeutic benefit while minimizing risk.

Methotrexaat Basic Pharma is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because methotrexate can be excreted in breast milk and may harm the infant. Effective contraception is required for women of child‑bearing potential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details (including cold‑chain if needed), and assists with import documentation.

Methotrexaat Basic Pharma (methotrexate) is a first‑line conventional disease‑modifying antirheumatic drug (DMARD) and is often preferred for its long‑track record, oral or injectable options, and cost‑effectiveness. Biologic agents such as TNF‑α inhibitors may be used when methotrexate alone is insufficient, but they are typically more expensive and require additional monitoring for infections.

Methotrexaat Basic Pharma should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability, and allow it to reach room temperature briefly before subcutaneous administration if required by the clinical protocol.

The product is supplied for subcutaneous injection. Healthcare professionals administer the dose using a sterile syringe, typically into the abdomen or thigh, following aseptic technique. The injection site may be rotated to reduce local irritation, and the exact administration schedule is set by the prescribing clinician.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to bone‑marrow suppression, acute renal failure, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for hepatic, renal, and hematologic parameters, and any signs of infection or respiratory distress require immediate medical attention.

Methotrexaat Basic Pharma is contraindicated in pregnant or breastfeeding women, patients with severe hepatic or renal impairment, those with active infections, and individuals with known hypersensitivity to methotrexate or any of its excipients. Caution is also advised for patients with pre‑existing lung disease or immunodeficiency.